Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Monane

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
European Journal of Preventive Cardiology|January 20, 2024
A polygenic risk score added to a QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical acceptance and clinical utility in the primary care settingAhmet Fuat, Ella Adlen, Mark Monane, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 16, 2024
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloidMatthew R Meyer, Kristopher M Kirmess, Stephanie Eastwood, et al.
Nature Medicine|April 9, 2025
Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platformSebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, et al.
Nature Reviews. Neurology|June 12, 2024
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's DiseaseSuzanne E Schindler, Douglas Galasko, Ana C Pereira, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 6, 2024
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's diseaseMichelle M Mielke, Matthew Anderson, J Wesson Ashford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 1, 2024
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's diseaseMichelle M Mielke, Matthew Anderson, J Wesson Ashford, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
European Journal of Preventive Cardiology|January 20, 2024
A polygenic risk score added to a QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical acceptance and clinical utility in the primary care settingAhmet Fuat, Ella Adlen, Mark Monane, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 16, 2024
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloidMatthew R Meyer, Kristopher M Kirmess, Stephanie Eastwood, et al.
Nature Medicine|April 9, 2025
Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platformSebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, et al.
Nature Reviews. Neurology|June 12, 2024
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's DiseaseSuzanne E Schindler, Douglas Galasko, Ana C Pereira, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 6, 2024
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's diseaseMichelle M Mielke, Matthew Anderson, J Wesson Ashford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 1, 2024
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's diseaseMichelle M Mielke, Matthew Anderson, J Wesson Ashford, et al.
Pageof 3